Ligand Pharmaceuticals Incorporated
Cash Flow Statement
| Line Item | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-51.9M | $86.1M | $18.2M | $-10.3M | $2.3M | $41.9M | $-17.5M | $404.0K |
| Depreciation & Amortization | $8.9M | $8.8M | $8.9M | $8.6M | $9.5M | $9.5M | $11.1M | $13.5M |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $11.1M | $7.3M | $5.7M | $6.9M | $7.2M | $5.9M | $29.1M | $12.6M |
| Net Cash from Operating Activities | $13.3M | $18.7M | $8.1M | $7.6M | $-82.0K | $33.9M | $53.5M | $20.5M |
| Investing Activities | ||||||||
| Capital Expenditures | $408.0K | $105.0K | $417.0K | $487.0K | $203.0K | $2.4M | $2.1M | $4.3M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-54.8M | $-3.8M | $-10.3M | $-19.5M | $7.6M | $10.5M | $-7.3M | $19.2M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $9.5M | $12.2M | $5.3M | $3.3M | $-67.8M | $-775.0K | $-5.3M | $-40.8M |
| Net Change in Cash | $-32.0M | $27.1M | $3.1M | $-8.6M | $-60.3M | $43.7M | $40.9M | $-1.2M |
| Free Cash Flow | $12.9M | $18.6M | $7.6M | $7.2M | $-285.0K | $31.5M | $51.3M | $16.2M |